Analysis of the efficacy of Ganning tablets combined with entecavir in the treatment of hepatitis B with elevated alpha-fetoprotein

doi:10.19871/j.cnki.xfcrbzz.2021.04.017

Abstract

Abstract: Objective To investigate the efficacy of Ganning tablets combined with entecavir in the treatment of hepatitis B with elevated alpha-fetoprotein, and the effect of alpha fetoprotein (AFP) and liver function. Methods A total of 60 hepatitis B patients with alpha-fetoprotein overexpression who were admitted to the Rugao Hospital of Nantong University from January 2016 to December 2019 were selected as the research objects, and they were randomly divided into a treatment group and a control group with 30 cases each. The control group was treated with entecavir, and the treatment group was treated with Ganning tablets on the basis of the control group. The treatment effects of the two groups were compared, and the alpha-fetoprotein levels of the two groups were detected and compared before and after 12, 24, and 48 weeks after treatment. HBV DNA copy number and liver function level. Results Two groups of patients were treated for 12, 24 and 48 weeks respectively. The normalization rate of alanine aminotransferase (ALT) and alpha-fetoprotein (AFP) in the treatment group was significantly higher than that in the control group (P<0.05); and the two groups After treatment, the HBV DNA copy number and AFP expression level of the patients were significantly decreased compared with before treatment (P<0.05), and the decline in the treatment group was significantly better than that of the control group (P<0.05). After 12, 24 and 48 weeks of treatment, the elasticity index of liver and spleen and portal vein diameter of the two groups were significantly decreased (P<0.05), and the decrease of the treatment group was significantly better than that of the control group (P<0.05). No serious adverse reactions occurred in the two groups of patients during treatment, and there was no significant difference in the incidence of adverse reactions such as mild nausea, insomnia, dizziness, and abdominal discomfort in the two groups (P>0.05). Conclusion Ganning tablets combined with Entecavir has a significant clinical effect in the treatment of hepatitis B with elevated alpha-fetoprotein. It can significantly reduce liver inflammation and fibrosis, improve hepatocyte proliferation and spleen elasticity index, and promote liver function recovery.

Key words: Ganning tablets, Alpha-fetoprotein, Hepatitis B, Curative effect, Entecavir

Ma Chenbin, Tian Zhi'ao. Analysis of the efficacy of Ganning tablets combined with entecavir in the treatment of hepatitis B with elevated alpha-fetoprotein[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(4): 339-342.

References

[1] PAN CQ, DAI E, BHAMIDIMARRI KR, et al.Clinical Features of Chronic Hepatitis B in Treatment-naive Asian Patients With Positive HBeAg and Coexisting Precore and/or Basal Core Promoter Mutations[J]. J Clin Gastroenterol, 2017, 51(3):261-265.
[2] HIDENORI, YASUKO S, KYOKO H, et al.A Case of Gallbladder Carcinoma Producing Alpha-Fetoprotein(AFP)with Metastatic Liver Tumor[J]. Gan To Kagaku Ryoho, 2017, 44(12):1182-1184.
[3] 杨旭, 邹园涛, 曾妮. 干扰素联合恩替卡韦治疗HBeAg阳性乙型肝炎的疗效及安全性分析[J]. 山东医药, 2017, 57(22):68-72.
[4] 田芝奥, 李慧, 吴霞, 等.阿德福韦酯联合肝宁片治疗甲胎蛋白升高的乙型肝炎患者的疗效[J]. 江苏医药, 2017, 43(15): 1082-1084.
[5] THIELE M, MADSEN BS, PROCOPET B, et al.Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease[J]. Ultraschall Med, 2017, 38(6):648-654.
[6] 王贵强, 王福生, 成军,等. 慢性乙型肝炎防治指南(2015年版)[J/CD]. 中华实验和临床感染病杂志(电子版), 2015, 19(5):1-18.
[7] 杨凯, 管世鹤, 张浩, 等.血清甲胎蛋白评估乙型肝炎患者肝脏显著炎症的临床应用[J].安徽医科大学学报, 2019, 54(7):1146-1149.
[8] 黄伟强, 董常峰. 弹性成像及血生化指标对肝纤维化的评价及研究进展[J/CD]. 新发传染病电子杂志, 2017, 2(2):117-121.
[9] 张茜, 邹琳, 童学科, 等. 恩替卡韦单药与联合重组人干扰素α-2b治疗HBeAg阳性乙型肝炎[J]. 中华传染病杂志, 2017, 35(12):751-753.
[10] 王学祥, 刘新群, 王正茂. 肝宁片联合异甘草酸镁治疗慢性病毒性肝炎的临床研究[J]. 现代药物与临床, 2018, 33(5):1097-1100.
[11] 李沁园,董常峰,姜伟. 超声弹性成像对肝纤维化的诊断及应用[J/CD]. 新发传染病电子杂志,2020,5(3):207-221.
[12] MOHAMMED TA, MAHA ZO, FATMA MOHAMED AE, et al.Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including 5 noninvasive indexes[J]. Medicine, 2018, 97(6):e9781.
[13] 赵建学, 吴意赟, 陆玮婷, 等. 恩替卡韦联合复方鳖甲软肝片对HBV DNA阳性乙型肝炎肝纤维化患者脾脏弹性指数及门静脉内径的影响[J]. 南京医科大学学报(自然科学版), 2017, 37(11):1504-1506.
[14] 王春妍, 文君, 周永和, 等. 声脉冲辐射力弹性成像技术对乙型肝炎后乙型肝炎患者食管静脉曲张的预测价值[J]. 中华肝脏病杂志, 2018, 26(7):499-502.
[15] 孙丹丹, 高艺花, 金成子, 等. 脾脏VTQ值与乙型肝炎肝纤维化分期[J]. 实用医学杂志, 2017, 33(3):388-390.
[16] ERIC JK, LAURA K, ZORAN S, et al.JOURNAL CLUB: Four-Dimensional Flow MRI-Based Splenic Flow Index for Predicting Cirrhosis-Associated Hypersplenism[J]. Am J Roentgenol, 2017, 209(1):1-9.
[17] 张潇月, 唐少珊. 实时剪切波弹性成像定量评价正常脾脏组织弹性[J]. 中国医学影像技术, 2016, 32(10):1523-1526.